Vitamin D Receptor Gene BsmI Polymorphism in Polish Patients with Systemic Lupus Erythematosus. (18th June 2013)

• Record Type: Journal Article
• Authors: Kaleta, Beata; Bogaczewicz, Jarosław; Robak, Ewa; Sysa-Jędrzejowska, Anna; Wrzosek, Małgorzata; Szubierajska, Weronika; Mróz, Piotr; Łukaszkiewicz, Jacek; Woźniacka, Anna
• Other Names: Pachucki J. Academic Editor.; Rillema J. A. Academic Editor.; Tamemoto H. Academic Editor.
• Is Part Of: ISRN endocrinology. Volume 2013(2013)
• Publication Date: 2013-06-18
• Subjects: Endocrinology -- Periodicals; Endocrine System Diseases; Endocrinology; Endocrinology; Electronic journals; Periodical; Fulltext; Internet Resources; Periodicals; Periodicals; 616.4
• DOI: 10.1155/2013/427818
• Languages: English
• ISSNs: 2090-4630

Abstract

Abstract : The hormonally active form of vitamin D3, 1, 25(OH)2 D3 (calcitriol), exerts actions through VDR receptor, which acts as a transcriptional factor. Calcitriol is an immunomodulator that affects various immune cells, and several studies link it to many autoimmune diseases. BsmI polymorphism affects the level of VDR gene transcription, transcript stability, and posttranscriptional modifications. It seems to be related to the systemic lupus erythematosus (SLE). Our study examined the characteristics of VDR gene BsmI polymorphism in Polish SLE patients and their relationship with clinical manifestations of the disease. We genotyped 62 patients with SLE and 100 healthy controls using the real-time PCR. There were no differences observed in the frequency of BsmI genotypes in SLE patients and in the control group. There was no significant correlation between BsmI genotypes and clinical symptoms of SLE, but the AA genotype correlates with higher levels of antinuclear antibodies (ANA) in this group (r = 0.438 ; P = 0.002 ). A larger study examining BsmI and other VDR gene polymorphisms is needed. It may allow explaining differences in the clinical picture of the disease and choosing a personalized therapy.